Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic User Fee Negotiators Struggling To Meet June Deadline

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA does not want to rush, but may consider splitting negotiators into small groups to deal with specific issues.
Advertisement

Related Content

Generic Drug User Fees Will Begin With The Backlog
Generic User Fees: API Manufacturers To Pay Less Than Finished Dose Firms
ANDA User Fees: Negotiators Close To Agreement, But Backlog Is Sticking Point
Generic User Fees Might Combine Inspection Visits, Boost Foreign Cooperation
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
FDA Could Face 13% Funding Cut Under House FY '12 Appropriations Bill
Generic User Fees Would Create 10-Month ANDA Review Time
PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers
Generic User Fees Have Four-Month Negotiating Window As Differences Narrow
Generic User Fees Have Four-Month Negotiating Window As Differences Narrow

Topics

Advertisement
UsernamePublicRestriction

Register

PS072229

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel